본문 바로가기
KERD
논문KCI 등재

Human Papillomavirus Type 16 E5 Protein as a Therapeutic Target

김상우|양주성
연세대학교의과대학 (Yonsei University College of Medicine)|2006.02|Yonsei Medical Journal|제47권 제1호|pp. 1-14

5

조회

0

다운로드

1

인용

0

참고문헌

주제분류의학일반

초록

Abstract

Cervical cancer is a progressive disease with an onset of one to two decades on average. During the productive replication stage, the Human papillomavirus (HPV) genome is maintained episomally in the infected cervical epithelium and early gene products, including E5, are expressed. Therefore, E5 has a potential to contribute to the HPV-associated carcinogenic process. In invasive malignancies, the HPV genomes are commonly integrated into the host genome, and E6 and E7 genes remain intact. However, the E5 is lost or, if present, under-expressed as compared with the E6 and E7 proteins. This suggests that E5 may play a critical role in the genesis of cervical cancer but less of a role in its persistence or progression. In the initiation of neoplasia and the premalignant stage, there are fewer malignant cells than in the invasive malignancies. Moreover, cells in the invasive malignant stage are found to have a very low level of MHC class I and II, which could hamper the presentation of the antigen and lead to a decreased immune response. Since the E5 protein is likely to play a role during the early tumorigenesis stage, a therapeutic vaccine to target and eliminate the E5-expressing cells may be a good strategy to prevent premalignant lesions from progressing toward invasive cervical cancers. This paper provides an overview of HPV-induced cervical carcinogenesis and strategies for designing prophylactic and therapeutic vaccines to prevent and cure the cervical cancer. In particular, focus will be on the rationale of targeting the E5 protein to develop therapeutic vaccines.

참고문헌 (63)

  1. "Human papillomavirus vaccines and prevention of cervical cancer", 55, pp.319~31 (2004)
  2. "Biology of human papillomaviruses", 82, pp.15~33 (2001)
  3. "Pathogenesis of human papillomaviruses in differentiating epithelia", 68, pp.362~72 (2004)
  4. "Transcriptional regulation of human papillomavirus type 16 LCR by different C", EBPbeta isoforms, 2000, pp.28, 42~50
  5. "The papillomavirus E2 regulatory proteins", 266, pp.18411~4 (1991)
  6. "Molecular and serological studies of human papillomavirus among patients with anal epidermoid carcinoma", 53, pp.377~81 (1993)
  7. "Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins", 89, pp.5799~803 (1992)
  8. "Control of human papillomavirus type 11 origin of replication by the E2 family of transcription regulatory proteins", 66, pp.5224~31 (1992)
  9. "The papillomavirus life cycle", 32(1), pp.7~15 (2005)
  10. "Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network", 352, pp.824~7 (1991)
  11. "Human papillomavirus type 16 E1 E4-induced G2 arrest is associated with cytoplasmic retention of active Cdk1", cyclin B1 complexes, 2005, pp.79, 3998~4011
  12. "Mechanisms of cell transformation by papillomavirus E5 proteins", 20, pp.7866~73 (2001)
  13. "Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high- risk human papillomavirus oncogene", 65, pp.6534~42 (2005)
  14. "Bovine papillomavirus E5 oncoprotein binds to the activated form of the platelet-derived growth factor beta receptor in naturally occurring bovine urinary bladder tumours" (2005)
  15. "Molecular mechanism of carcinogenesis by human papillomavirus-16", 27, pp.73~86 (2000)
  16. "HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes", 8, pp.3905~10 (1989)
  17. "HPV16 participates in progressive transformation of normal epidermal cells", 16, pp.549~61 (1989)
  18. "Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage", 90, pp.3988~92 (1993)
  19. "Human antibodies react with an epitope of the human papillomavirus type 6b L1 open reading frame which is distinct from the type-common epitope", 63, pp.809~18 (1989)
  20. "The biochemical and biological functions of human papillomavirus type 16 E5 protein", 148, pp.1445~53 (2003)
  21. "Human papillomavirus type 16 E5 protein localizes to the Golgi apparatus but does not grossly affect cellular glycosylation", 145, pp.2183~91 (2000)
  22. "Overexpression, purification,and structural analysis of the hydrophobic E5 protein from human papillomavirus type 16", 30, pp.1~10 (2003)
  23. "Human papillomavirus type 16 E5 protein colocalizes with the antiapoptotic Bcl-2 protein", 149, pp.1745~59 (2004)
  24. "Binding of human papillomavirus 16 E5 to the 16 kDa subunit c (proteolipid) of the vacuolar H+-ATPase can be dissociated from the E5-mediated epidermal growth factor receptor overactivation", 19, pp.3727~32 (2000)
  25. "The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors", 59, pp.21~32 (1989)
  26. "Activation of the platelet-derived growth factor receptor by the bovine papillomavirus E5 transforming protein", 10, pp.845~55 (1991)
  27. "HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes", 24, pp.2585~8 (2005)
  28. "Enhancement of EGF- and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein", 15, pp.1437~44 (1997)
  29. "The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes", 69, pp.3185~92 (1995)
  30. "The E5 gene of HPV-16 enhances keratinocyte immortalization by full-length DNA", 223, pp.251~4 (1996)
  31. "Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor", 7, pp.27~32 (1992)
  32. "Expression of c-jun, c-fos and MDM2 mRNA in cultured kerotinocytes through transfecting HPV16", 81, pp.171~3 (2001)
  33. "Human papillomavirus type 11 and 16 E5 represses p21(WafI", SdiI, pp.1996, 70[DOI]
  34. "Expression of p21", WAF-1, status of apoptosis and p53 mutationin esophageal squamous cell carcinoma with HPV infection, 2002, pp.52, 442~50
  35. "Duration of HPV-associated risk for high- grade cervical intraepithelial neoplasia", (21) (2005)
  36. "Expression of HPV16 E6 or E7 increases integration of foreign DNA", 13, pp.427~31 (1996)
  37. "Functional analysis of the human papillomavirus type 16 E1-E4 protein provides a mechanism for in vivo and in vitro keratin filament reorganization", 78, pp.821~33 (2004)
  38. "p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein", 91, pp.5320~4 (1994)
  39. "Study on the carcinogenic mechanism of human papillomavirus type l6 E7 protein in cervical carcinoma", 14, pp.117~20 (2000)
  40. "Genetic abnormalities and HPV status in cervical and vulvar squamous cellcarcinomas", 157, pp.42~8 (2005)
  41. "Human papillomavirus type 16 E6 oncogene and expression of P53 RB and PCNA in human cervical carcinoma", 11, pp.271~3 (1997)
  42. "Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro", 208, pp.111~20 (1995)
  43. "The biological activities of the human papillomavirus type 16 E6", E7 cDNAs cloned from the SiHa cervical carcinoma cell line, 1993, pp.68, 849~61
  44. "The E7 oncoprotein of high-risk human papillomavirus type 16 enters the nucleus via a nonclassical Ran-dependent pathway", 317, pp.13~23 (2003)
  45. "HPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16", 279, pp.361~9 (2001)
  46. "Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice", 73, pp.9609~13 (1999)
  47. "Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine", 23, pp.3634~41 (2005)
  48. "Papillomavirus-like particle vaccines", 28, pp.50~4 (2001)
  49. "Expression of human papillomavirus type 16 L1 protein in transgenic tobacco plants", 37, pp.153~8 (2005)
  50. "Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles", 95, pp.1128~37 (2003)
  51. "Vaccines against human papillomavirus and cervical cancer: promises and challenges", 10, pp.528~38 (2005)
  52. "Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines", 290, pp.350~60 (2001)
  53. "Induction of human papilloma virus E6", E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6, pp.2005, 12[DOI]
  54. "Viral recombinant vaccines to the E6 and E7 antigens of HPV-16", 270, pp.146~61 (2000)
  55. "Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer", 74, pp.2888~94 (2000)
  56. "Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7", 4, pp.2103~9 (1998)
  57. "Phase IIa safety and immunogenicity of a therapeutic vaccine,TA-GW, in persons with genital warts", 179, pp.612~8 (1999)
  58. "Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7", 121, pp.216~25 (2000)
  59. "Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins", 112, pp.109~17 (2003)
  60. "Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18- positive cervical cancer", 73, pp.5402~10 (1999)
  61. "Proliferative T-cell responses to human papillomavirus type 16 E5 are decreased amongst women with high-grade neoplasia", 79, pp.1971~6 (1998)
  62. "Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth", 74, pp.9083~9 (2000)
  63. "Cytotoxic-T lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL", 6 mice, 2004, pp.78, 1333~43

관련 논문AI추천

The Role of HPV E6 and E7 Oncoproteins in HPV-associated Cervical CarcinogenesisEun-Kyoung Yim, Jong-Sup Park대한암학회 · Cancer Research and Treatment2005 · 제37권 제6호Attenuated Nuclear Factor Kappa B Activity by E7 Protein of Human Papillomavirus Type 2 in Human Epidermal Keratinocytes류윤희, 박영민, 이지현, 최순영, 한주희대한피부과학회 · Annals of Dermatology2017 · 제29권 제3호Immunization with Adenoviral Vectors Carrying Recombinant IL-12 and E7 Enhanced the Antitumor Immunity against Human Papillomavirus 16-associated TumorByoung Don Han, Do Gang Kim, Eun Kyung Park, Heung Jae Chun, Hyun Sun Jin, Jeong Im Sin, Joon Mo Lee, Su Mi Bae, Sung Eun NamKoong, Woong Shick Ahn, Young Wook Kim대한암학회 · Cancer Research and Treatment2005 · 제37권 제1호Cell-Specific Growth Inhibition of Human Cervical Cancer Cell by Recombinant Adenovirus p53 in vitro and in vivoChong Kook Kim, Jin Young Yoo, Joo Hee Yoon, Joon Mo Lee, Sang Lyun Nam, Su Mi Bae, Sung Eun Namkoong, Woong Shick Ahn, Yong-Wan Kim, Yong Wook Kim, Young-Seok Seo대한암학회 · Cancer Research and Treatment2003 · 제35권 제3호Cell Cycle Regulatory Protein Expression Profiles by Adenovirus p53 Infection in Human Papilloma Virus-associated Cervical Cancer CellsByoung-Don Han, Chong-Kook Kim, Do Kang Kim, Dong-Chun Park, Eun-Kyung Park, Soo-Young Hur, Su-Mi Bae, Sun-Young Kwak, Woong-Shick Ahn, Yong-Seok Lee, Yong-Wook Kim, Young- Joo Lee대한암학회 · Cancer Research and Treatment2006 · 제38권 제3호Aberrant Cell Cycle Regulation in Cervical Carcinoma김영태, Min Zhao연세대학교의과대학 · Yonsei Medical Journal2005 · 제46권 제5호

이 간행물의 다른 논문 (12건)

Further Increase of Vancomycin-Resistant Enterococcus faecium, Amikacin- and Fluoroquinolone-Resistant Klebsiella pneumoniae, and Imipenem-Resistant Acinetobacter spp. in Korea정석훈, 박기형, 하경임, 정윤섭, 이경원, 용동은, 신종희, 임환섭pp. 43-54Comparison of Efficacy of Cefoperazone/Sulbactam and Imipenem/Cilastatin for Treatment of Acinetobacter Bacteremia김연아, 용동은, 이경원, 송영구, 최준용, 윤희정, 신소연, 김창오, 박윤선, 김준명, 김영근, 김명수pp. 63-69Radiologic and Clinical Features of Idiopathic Granulomatous Lobular Mastitis Mimicking Advanced Breast Cancer정우희, 김은경, 이한경, 이제희, 곽규성, 오기근pp. 78-84Quantitative EMG Changes During 12-Week DeLorme's Axiom Strength Training조상현, 이영희, 권오윤, 신화경pp. 93-104The Actual Five-year Survival Rate of Hepatocellular Carcinoma Patients after Curative Resection박준성, 최진섭, 윤동섭, 이우정, 김병로, 이재길, 강창무, 김경식pp. 105-112
원문 보기